<p>Voloridge Investment Management LLC 在最近向證券交易委員會提交的 13F 文件中表示，在第四季度將其在 10x Genomics, Inc. (NASDAQ:TXG - 免費報告) 的持股比例提高了 12.1%。該公司在此期間購買了額外的 171,161 股後，持有 1,585,965 股該公司的股票。根據其最近的 SEC 文件，Voloridge Investment Management LLC 持有 10x Genomics 1.31% 的股份，價值 22,774,000 美元。</p>
<ul>
<li>戰略性買入點亮這隻生物科技股票：是時候投資了嗎？</li>
</ul>
<p>其他幾家機構投資者和對沖基金最近也調整了對 TXG 的持股。RA Capital Management L.P. 在第四季度購買了 10x Genomics 的新股份，價值約 47,092,000 美元。D. E. Shaw &amp; Co. Inc. 在第四季度購買了 10x Genomics 的新股份，估計價值約 17,499,000 美元。ARK Investment Management LLC 在第四季度將其在 10x Genomics 的持股比例提高了 11.1%。ARK Investment Management LLC 目前持有 11,944,057 股該公司的股票，價值 171,517,000 美元，此前在上個季度購買了額外的 1,193,712 股。Two Sigma Investments LP 在第四季度將其在 10x Genomics 的持股比例提高了 291.2%。Two Sigma Investments LP 目前持有 1,319,487 股該公司的股票，價值 18,948,000 美元，此前在上個季度購買了額外的 982,203 股。最後，Two Sigma Advisers LP 在第四季度將其在 10x Genomics 的持股比例提高了 240.6%。Two Sigma Advisers LP 目前持有 1,236,200 股該公司的股票，價值 17,752,000 美元，此前在上個季度購買了額外的 873,200 股。84.68% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾位股票研究分析師最近對該公司發表了看法。瑞銀集團將 10x Genomics 的目標股價從 14.00 美元下調至 12.00 美元，並在 5 月 13 日的研究報告中對該股票給予了 “中性” 評級。Stifel Nicolaus 將 10x Genomics 的目標股價從 21.00 美元下調至 18.00 美元，並在 2 月 13 日的報告中對該股票給予了 “買入” 評級。Stephens 在 5 月 15 日的報告中重申了 “增持” 評級，並對 10x Genomics 的股票設定了 14.00 美元的目標股價。Leerink Partners 將 10x Genomics 的股票評級從 “跑贏大盤” 下調至 “市場表現”，並在 2 月 13 日的報告中將其目標股價從 25.00 美元下調至 12.00 美元。最後，高盛集團將 10x Genomics 的目標股價從 7.50 美元下調至 6.50 美元，並在 5 月 12 日的報告中對該股票給予了 “賣出” 評級。一位研究分析師對該股票給予了賣出評級，八位分析師給予了持有評級，八位分析師給予了買入評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “持有”，共識目標價為 15.81 美元。</p>
<p><strong>查看我們對 10x Genomics 的最新股票分析</strong></p>
<h2>10x Genomics 的內部買賣</h2>
<p>在其他新聞中，內部人士 Benjamin J. Hindson 於 2 月 24 日星期一出售了 4,573 股該公司的股票。該股票以平均價格 11.07 美元出售，總價值為 50,623.11 美元。交易後，內部人士現在直接持有 335,324 股該公司的股票，價值 3,712,036.68 美元。此交易代表其持股比例減少了 1.35%。該交易在向 SEC 提交的文件中披露，文件可在此鏈接查看。此外，首席執行官 Serge Saxonov 於 2 月 24 日星期一出售了 5,092 股該公司的股票。該股票以平均價格 11.07 美元出售，總價值為 56,368.44 美元。交易完成後，首席執行官現在持有 879,482 股該公司的股票，價值約 9,735,865.74 美元。此交易代表其持股比例減少了 0.58%。該銷售的披露信息可以在這裏找到。公司內部人士持有該公司 9.39% 的股票。</p>
<h2>10x Genomics 股票上漲 2.6%</h2>
<p>NASDAQ TXG 的股票在週五開盤時為 8.54 美元。10x Genomics, Inc. 的 12 個月低點為 6.78 美元，12 個月高點為 24.76 美元。該公司的市值為 10.4 億美元，市盈率為 -5.62，貝塔值為 1.94。該公司的 50 日移動平均線為 8.63 美元，200 日移動平均線為 12.15 美元。</p>
<p>10x Genomics (NASDAQ:TXG - 獲取免費報告) 最近於 5 月 8 日宣佈了其季度財報。該公司報告本季度每股收益為（0.36）美元，超過分析師一致預期的（0.45）美元，超出幅度為 0.09 美元。10x Genomics 的淨利潤率為 -29.90%，股本回報率為 -25.40%。該公司本季度的收入為 1.5488 億美元，而分析師預期為 1.3191 億美元。在去年同期，該公司的每股收益為（0.50）美元。該公司的季度收入同比下降了 2.3%。整體來看，股票分析師預計 10x Genomics, Inc. 在當前財年將發佈 -1.43 的每股收益。</p>
<h2>10x Genomics 公司簡介</h2>
<p>（免費報告）</p>
<p>10x Genomics, Inc. 是一家生命科學技術公司，開發和銷售用於分析生物系統的儀器、耗材和軟件，業務覆蓋美國、歐洲、中東、非洲、中國和亞太地區。該公司提供 chromium、chromium connect 和 chromium controller 儀器、微流控芯片、載玻片、試劑和其他耗材產品。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 10x Genomics</li>
<li>三隻值得購買的醫療保健分紅股票</li>
<li>Joby 股票的波動：近期下跌的原因是什麼？</li>
<li>經紀評級在股票選擇中的重要性</li>
<li>為什麼嘉年華可能是終極非科技增長股票</li>
<li>股票情緒分析：它是如何運作的</li>
<li>超級微型計算機股票在沙特訂單中開闢新路徑</li>
</ul>
<p><strong>想知道其他對 TXG 感興趣的對沖基金持有哪些股票嗎？</strong> 請訪問 HoldingsChannel.com 獲取 10x Genomics, Inc. (NASDAQ:TXG - 免費報告) 的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFhH?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFhH"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 10x Genomics 嗎？</h2>
<p>在考慮投資 10x Genomics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 10x Genomics 並不在名單上。</p>
<p>雖然 10x Genomics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Voloridge Investment Management LLC 在第四季度將其在 10X Genomics, Inc. (NASDAQ:TXG) 的持股增加了 12.1%，目前擁有 1,585,965 股，價值 2277 萬美元。其他機構投資者也增加了他們的持股。分析師對該股票的評級不一，普遍目標價為 15.81 美元。10X Genomics 的股票最近上漲了 2.6%，交易價格為 8.54 美元，市值為 10.4 億美元，市盈率為 -5.62</p>

<p>Voloridge Investment Management LLC lifted its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 12.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,585,965 shares of the company's stock after purchasing an additional 171,161 shares during the period. Voloridge Investment Management LLC owned 1.31% of 10x Genomics worth $22,774,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Voloridge Investment Management LLC 在最近向證券交易委員會提交的 13F 文件中表示，在第四季度將其在 10x Genomics, Inc. (NASDAQ:TXG - 免費報告) 的持股比例提高了 12.1%。該公司在此期間購買了額外的 171,161 股後，持有 1,585,965 股該公司的股票。根據其最近的 SEC 文件，Voloridge Investment Management LLC 持有 10x Genomics 1.31% 的股份，價值 22,774,000 美元。</p>
</div><ul>
<li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li>
</ul>
<div class="lb-trans"><ul>
<li>戰略性買入點亮這隻生物科技股票：是時候投資了嗎？</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also recently modified their holdings of TXG. RA Capital Management L.P. purchased a new stake in shares of 10x Genomics in the 4th quarter worth about $47,092,000. D. E. Shaw &amp; Co. Inc. bought a new stake in shares of 10x Genomics during the fourth quarter valued at approximately $17,499,000. ARK Investment Management LLC boosted its position in shares of 10x Genomics by 11.1% during the fourth quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company's stock valued at $171,517,000 after purchasing an additional 1,193,712 shares in the last quarter. Two Sigma Investments LP boosted its position in shares of 10x Genomics by 291.2% during the fourth quarter. Two Sigma Investments LP now owns 1,319,487 shares of the company's stock valued at $18,948,000 after purchasing an additional 982,203 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its position in shares of 10x Genomics by 240.6% during the fourth quarter. Two Sigma Advisers LP now owns 1,236,200 shares of the company's stock valued at $17,752,000 after purchasing an additional 873,200 shares in the last quarter. 84.68% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金最近也調整了對 TXG 的持股。RA Capital Management L.P. 在第四季度購買了 10x Genomics 的新股份，價值約 47,092,000 美元。D. E. Shaw &amp; Co. Inc. 在第四季度購買了 10x Genomics 的新股份，估計價值約 17,499,000 美元。ARK Investment Management LLC 在第四季度將其在 10x Genomics 的持股比例提高了 11.1%。ARK Investment Management LLC 目前持有 11,944,057 股該公司的股票，價值 171,517,000 美元，此前在上個季度購買了額外的 1,193,712 股。Two Sigma Investments LP 在第四季度將其在 10x Genomics 的持股比例提高了 291.2%。Two Sigma Investments LP 目前持有 1,319,487 股該公司的股票，價值 18,948,000 美元，此前在上個季度購買了額外的 982,203 股。最後，Two Sigma Advisers LP 在第四季度將其在 10x Genomics 的持股比例提高了 240.6%。Two Sigma Advisers LP 目前持有 1,236,200 股該公司的股票，價值 17,752,000 美元，此前在上個季度購買了額外的 873,200 股。84.68% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several equities research analysts recently weighed in on the company. UBS Group dropped their price target on 10x Genomics from $14.00 to $12.00 and set a &#34;neutral&#34; rating on the stock in a research report on Tuesday, May 13th. Stifel Nicolaus cut their price objective on shares of 10x Genomics from $21.00 to $18.00 and set a &#34;buy&#34; rating on the stock in a report on Thursday, February 13th. Stephens restated an &#34;overweight&#34; rating and issued a $14.00 price objective on shares of 10x Genomics in a report on Thursday, May 15th. Leerink Partners cut shares of 10x Genomics from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and cut their price objective for the stock from $25.00 to $12.00 in a report on Thursday, February 13th. Finally, The Goldman Sachs Group cut their price objective on shares of 10x Genomics from $7.50 to $6.50 and set a &#34;sell&#34; rating on the stock in a report on Monday, May 12th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and a consensus price target of $15.81.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對該公司發表了看法。瑞銀集團將 10x Genomics 的目標股價從 14.00 美元下調至 12.00 美元，並在 5 月 13 日的研究報告中對該股票給予了 “中性” 評級。Stifel Nicolaus 將 10x Genomics 的目標股價從 21.00 美元下調至 18.00 美元，並在 2 月 13 日的報告中對該股票給予了 “買入” 評級。Stephens 在 5 月 15 日的報告中重申了 “增持” 評級，並對 10x Genomics 的股票設定了 14.00 美元的目標股價。Leerink Partners 將 10x Genomics 的股票評級從 “跑贏大盤” 下調至 “市場表現”，並在 2 月 13 日的報告中將其目標股價從 25.00 美元下調至 12.00 美元。最後，高盛集團將 10x Genomics 的目標股價從 7.50 美元下調至 6.50 美元，並在 5 月 12 日的報告中對該股票給予了 “賣出” 評級。一位研究分析師對該股票給予了賣出評級，八位分析師給予了持有評級，八位分析師給予了買入評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “持有”，共識目標價為 15.81 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on 10x Genomics</strong></p>
<div class="lb-trans"><p><strong>查看我們對 10x Genomics 的最新股票分析</strong></p>
</div><h2>Insider Buying and Selling at 10x Genomics</h2>
<div class="lb-trans"><h2>10x Genomics 的內部買賣</h2>
</div><p>In other news, insider Benjamin J. Hindson sold 4,573 shares of the firm's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the transaction, the insider now directly owns 335,324 shares in the company, valued at $3,712,036.68. This trade represents a 1.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Serge Saxonov sold 5,092 shares of the firm's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the completion of the transaction, the chief executive officer now owns 879,482 shares in the company, valued at approximately $9,735,865.74. This trade represents a 0.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 9.39% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 Benjamin J. Hindson 於 2 月 24 日星期一出售了 4,573 股該公司的股票。該股票以平均價格 11.07 美元出售，總價值為 50,623.11 美元。交易後，內部人士現在直接持有 335,324 股該公司的股票，價值 3,712,036.68 美元。此交易代表其持股比例減少了 1.35%。該交易在向 SEC 提交的文件中披露，文件可在此鏈接查看。此外，首席執行官 Serge Saxonov 於 2 月 24 日星期一出售了 5,092 股該公司的股票。該股票以平均價格 11.07 美元出售，總價值為 56,368.44 美元。交易完成後，首席執行官現在持有 879,482 股該公司的股票，價值約 9,735,865.74 美元。此交易代表其持股比例減少了 0.58%。該銷售的披露信息可以在這裏找到。公司內部人士持有該公司 9.39% 的股票。</p>
</div><h2>10x Genomics Stock Up 2.6%</h2>
<div class="lb-trans"><h2>10x Genomics 股票上漲 2.6%</h2>
</div><p>Shares of NASDAQ TXG opened at $8.54 on Friday. 10x Genomics, Inc. has a twelve month low of $6.78 and a twelve month high of $24.76. The firm has a market cap of $1.04 billion, a P/E ratio of -5.62 and a beta of 1.94. The company has a 50 day moving average of $8.63 and a 200 day moving average of $12.15.</p>
<div class="lb-trans"><p>NASDAQ TXG 的股票在週五開盤時為 8.54 美元。10x Genomics, Inc. 的 12 個月低點為 6.78 美元，12 個月高點為 24.76 美元。該公司的市值為 10.4 億美元，市盈率為 -5.62，貝塔值為 1.94。該公司的 50 日移動平均線為 8.63 美元，200 日移動平均線為 12.15 美元。</p>
</div><p>10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. The company had revenue of $154.88 million during the quarter, compared to analyst estimates of $131.91 million. During the same period in the previous year, the business earned ($0.50) EPS. The firm's revenue for the quarter was down 2.3% on a year-over-year basis. As a group, equities analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>10x Genomics (NASDAQ:TXG - 獲取免費報告) 最近於 5 月 8 日宣佈了其季度財報。該公司報告本季度每股收益為（0.36）美元，超過分析師一致預期的（0.45）美元，超出幅度為 0.09 美元。10x Genomics 的淨利潤率為 -29.90%，股本回報率為 -25.40%。該公司本季度的收入為 1.5488 億美元，而分析師預期為 1.3191 億美元。在去年同期，該公司的每股收益為（0.50）美元。該公司的季度收入同比下降了 2.3%。整體來看，股票分析師預計 10x Genomics, Inc. 在當前財年將發佈 -1.43 的每股收益。</p>
</div><h2>10x Genomics Profile</h2>
<div class="lb-trans"><h2>10x Genomics 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.</p>
<div class="lb-trans"><p>10x Genomics, Inc. 是一家生命科學技術公司，開發和銷售用於分析生物系統的儀器、耗材和軟件，業務覆蓋美國、歐洲、中東、非洲、中國和亞太地區。該公司提供 chromium、chromium connect 和 chromium controller 儀器、微流控芯片、載玻片、試劑和其他耗材產品。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than 10x Genomics</li>
<li>3 Healthcare Dividend Stocks to Buy</li>
<li>Turbulence for Joby Shares: What's Behind the Recent Dip?</li>
<li>The Significance of Brokerage Rankings in Stock Selection</li>
<li>Why Carnival Could Be the Ultimate Non-Tech Growth Stock</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>Super Micro Computer Stock Clears New Path Higher on Saudi Orders</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 10x Genomics</li>
<li>三隻值得購買的醫療保健分紅股票</li>
<li>Joby 股票的波動：近期下跌的原因是什麼？</li>
<li>經紀評級在股票選擇中的重要性</li>
<li>為什麼嘉年華可能是終極非科技增長股票</li>
<li>股票情緒分析：它是如何運作的</li>
<li>超級微型計算機股票在沙特訂單中開闢新路徑</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TXG?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXG - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他對 TXG 感興趣的對沖基金持有哪些股票嗎？</strong> 請訪問 HoldingsChannel.com 獲取 10x Genomics, Inc. (NASDAQ:TXG - 免費報告) 的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFhH" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TXG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in 10x Genomics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 10x Genomics 嗎？</h2>
</div><p>Before you consider 10x Genomics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 10x Genomics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 10x Genomics 並不在名單上。</p>
</div><p>While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 10x Genomics 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Voloridge Investment Management LLC 增持了 10x Genomics, Inc.（NASDAQ:TXG）的股份